# A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

> **NCT02382939** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 92 (actual)

## Conditions studied

- Adult Growth Hormone Deficiency
- Growth Hormone Disorder

## Interventions

- **DRUG:** somapacitan
- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT02382939
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-12
- **Primary completion:** 2016-01-04
- **Final completion:** 2016-01-04
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382939, "A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT02382939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*